All In Biotech

Drug Trial Radar · NCT05296798

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 922 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

922

Planned (sponsor's estimate)

Start

Jul 18, 2022

Primary completion

Jun 15, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.

Conditions

  • Locally Advanced or Metastatic Breast Cancer

Interventions

  • PhesgoDrug

    Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).

  • GiredestrantDrug

    A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.

  • DocetaxelDrug

    During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.

  • PaclitaxelDrug

    During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.

  • LHRH AgonistDrug

    A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.

  • Optional Endocrine Therapy of Investigator's ChoiceDrug

    For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1Time frame: From randomization for maintenance therapy to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 53 months)

Locations

198 sites in 29 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center, Inc

    Tucson, Arizona

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Maryland Oncology Hematology - Annapolis

    Annapolis, Maryland

  • West Cancer Center

    Germantown, Tennessee

  • Texas Oncology - DFW

    Dallas, Texas

  • Texas Oncology - El Paso

    El Paso, Texas

  • Swedish Cancer Institute - Edmonds Campus

    Edmonds, Washington

  • Swedish Cancer Institute - Issaquah

    Issaquah, Washington

  • Swedish Cancer Institute

    Seattle, Washington

  • Centro Oncologico Korben

    Ciudad Autonoma Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Fundacion Centro Oncologico de Integracion Regional (COIR)

    Mendoza, Argentina

  • Instituto de Oncología de Rosario

    Rosario, Argentina

  • Hospital Provincial del Centenario

    Rosario, Argentina

  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica

    San Juan, Argentina

  • Centro de Investigaciones Médicas y Desarrollo LC S.R.L

    Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

  • GHdC Site Les Viviers

    Charleroi, Belgium

  • UZ Gent

    Ghent, Belgium

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Clinique Ste-Elisabeth

    Namur, Belgium

  • Pronutrir - suporte nutricional e quimioterapia ltda.

    Fortaleza, Ceará, Brazil

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, Brazil

  • Hospital Araujo Jorge

    Goiânia, Goiás, Brazil

  • Hospital do Câncer de Londrina

    Londrina, Paraná, Brazil

  • Hospital do Cancer de Pernambuco - HCP

    Recife, Pernambuco, Brazil

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Amor Amazônia

    Porto Velho, Rondônia, Brazil

  • Fundação Pio XII Hospital de Câncer de Barretos

    Barretos, São Paulo, Brazil

  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

    São Paulo, São Paulo, Brazil

  • Affiliated Hospital of Hebei University

    Baoding, China

  • Peking University People's Hospital

    Beijing, China

  • the First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • The First Hospital of Jilin University

    Changchun, China

  • Hunan Cancer Hospital

    Changsha, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • West China Hospital - Sichuan University

    Chengdu, China

  • No. 900 Hospital (Fuzhou General Hospital)

    Fuzhou, China

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.